Duey Marc 4

4 · Aprea Therapeutics, Inc. · Filed Jun 17, 2026

AI-generated summary of this filing

Updated Jun 17, 2026

Aprea (APRE) Director Marc Duey Receives Restricted Stock Award

What Happened

Marc Duey, a director of Aprea Therapeutics (APRE), was awarded a total of 15,690 restricted stock units (RSUs) on June 16, 2026. The grant is recorded as two items: 3,135 shares and 12,555 derivative shares, each at $0.00 (no cash purchase).

Key Details

Transaction date: June 16, 2026; Form 4 filed June 17, 2026 (timely filing).
Grant amounts: 3,135 shares and 12,555 RSUs — total 15,690 RSUs; grant price shown as $0.00 (compensation award).
Vesting/settlement: These RSUs vest and will be settled into common stock on June 16, 2027, contingent on continued board service and subject to certain acceleration provisions (Footnote F1).
Beneficial ownership: The reporting person disclaims beneficial ownership of these securities (Footnote F2).
Post-transaction holdings: The filing does not specify the total shares owned after the grant.
Note: The filing shows no cash purchase or sale; this is a compensation award rather than a market transaction.

Context

RSUs are a form of equity compensation: they convert to actual shares only if vesting conditions are met. Because these units are grants tied to service, they reflect company compensation practices rather than an outright “buy” or “sell” signal by the insider.
No option exercise, sale, or 10b5-1 plan was reported in this filing.

Form 4

Period: 2026-06-16

Director

Transactions

Award
Common Stock
[F1]
2026-06-16+3,135→ 259,290 total
Award
Stock Options (Right to Buy)
[F3]
2026-06-16+12,555→ 12,555 total
Exercise: $0.73Exp: 2036-06-16→ Common Stock (12,555 underlying)

Holdings

Footnotes (3)

[F1]These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
[F2]The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.
[F3]The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

Signature

/s/ John Hamill, as Attorney-in-Fact|2026-06-17

1 file